Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026
Zydus Therapeutics, the US-based innovation-focused specialty arm of Zydus Lifesciences, has announced promising results from a late-stage clinical trial of its experimental drug Saroglitazar. The drug is being tested for Primary Biliary Cholangitis (PBC) – a rare and progressive autoimmune liver disease which gradually destroys the bile ducts. The company plans to submit a US…